otitis externa

Otitis externa Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageOtitis externa MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:27 Aug 2023Last updated:21 Sep 2023SummaryAcute otitis externa (AOE) is a diffuse inflammation of the external ear canal that is most commonly caused by Pseudomonas aeruginosa and Staphylococcus aureus.Presents with rapid onset of ear pain, tenderness, itching, aural fullness, and hearing loss.More common in children and young adults.Fungal otitis externa is a fungal infection of the external ear caused by moulds and yeasts, which presents in a similar way to acute bacterial otitis externa.Necrotising otitis externa infection (also called malignant otitis

Otitis externa CHQ-GDL-00720 – Otitis Externa: Emergency Management in Children - 1 - Otitis Externa: Emergency Management in Children Document ID CHQ-GDL-00720 Version no. 3.0 Approval date 16/02/2023 Executive sponsor Executive Director Medical Services Effective date 16/02/2023 Author/custodian Director Paediatric Emergency Medicine, CHQ Review date 16/02/2026 Supersedes 2.0 Applicable to Emergency Department Medical & Nursing staff working at Children’s Health Queensland Authorisation Executive Director Clinical Services Purpose This procedure provides guidance to clinicians involved in emergency department management of children with otitis externa. Scope This guideline applies to all staff involved in the acute care and management of children with otitis externa

Otitis externa CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If you believe you are seeing

Efficacy of 1.5% levofloxacin otic solution in treating acute otitis externa: A post hoc analysis of ENT103-3001, a multicenter randomized double-blind parallel-group placebo-controlled phase III study in otitis media with persistent otorrhea. In this post hoc analysis, we aimed to evaluate the efficacy of 1.5% levofloxacin (LVFX) otic solution for the treatment of acute otitis externa (AOE ) in patients with nonintact tympanic membrane (NTM) accompanied by chronic suppurative and acute otitis media. Digital endoscopic images of the tympanic membrane and cavity were evaluated. In addition, the full analysis set from the original ENT103-3001 study was analyzed to determine the efficacy of the 1.5% LVFX otic solution in treating patients with otitis media with persistent otorrhea. AOE

Treatment Response Evaluation in Necrotizing Otitis Externa Using 18F-FDG-PET Imaging. This study aims to identify 18F-FDG-PET imaging features for improving treatment response evaluation in patients with necrotizing otitis externa (NOE), aiding in the difficult differentiation between sterile inflammation and active infection. Retrospective cohort study. Tertiary hospital. Patients diagnosed

Evaluation of the clinical and radiological features of patients with Malignant otitis externa (MOE). Malignant otitis externa (MOE) is a life-threatening infection of the external auditory canal and temporal bone. This study is designed to identify the clinical features, predisposing factors, radiological findings, complications, diagnoses, and management of MOE patients. Retrospective cross

Auricular nerve block for otitis externa: A case series. Acute otitis externa (OE) is a prevalent infectious condition of the external ear canal, often presenting with painful inflammation and purulent drainage. Sensory innervation of the external ear and canal involves several nerves, including the auriculotemporal, lesser occipital, great auricular, and auricular branch of the vagus nerve

Otitis externa Otitis externa - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates * Specialties  * Guidelines * Images and videos * References * Patient leaflets Log in or subscribe to access all of BMJ Best PracticeLast reviewed: 13 Jun 2022Last updated: 02 Sep 2021SummaryAcute otitis externa is a diffuse inflammation of the external ear canal that is most commonly caused byPseudomonas aeruginosa and Staphylococcus aureus.Presents with rapid onset

Changes in antimicrobial resistance in acute otitis media and otitis externa. Acute otitis media (AOM) and otitis externa (OE) are common ear infections which may warrant antibiotic therapy. For many infections, there is a rise in antimicrobial resistance, which is associated with treatment failure, morbidity, prolonged hospitalisation and mortality. This study aimed to identify longitudinal

Diagnostic accuracy of eosinophil-to-lymphocyte ratio and eosinophil-to-neutrophil ratio as biomarkers for differentiating between fungal and bacterial infection in necrotising otitis externa. Necrotizing otitis externa (NOE) is a serious, progressive, and potentially life-threatening infection of the external auditory canal, affecting soft tissue and bone. The most common organism causing NOE

Improving otitis externa management in secondary care through a standardised treatment algorithm. Otitis externa is a common condition managed by junior doctor-led ENT clinics in secondary/tertiary care, but no national guidelines exist for presentations in these settings. The aim of this study was to implement a treatment algorithm to support junior doctors and improve otitis externa management . Baseline data were retrospectively collected for 16 weeks. A standardised otitis externa treatment algorithm was then implemented, and 16 weeks of data prospectively gathered. A second improvement cycle was completed thereafter focusing on topical antibiotics and water precaution advice. Overall, 202 cases of otitis externa managed between November 2021 to October 2022 were reviewed. Following

Pediatric Necrotizing Otitis Externa: A Scoping Review. This review sought to answer the following research question: What are the characteristics of pediatric necrotizing otitis externa (NOE)? Moreover, we wanted to highlight the clinical importance of the current limitations in the literature. A scoping review was performed to determine what is known about NOE in the pediatric population. Four

Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treating acute otitis externa (AOE) compared with ciprofloxacin, 0.3%, or fluocinolone acetonide, 0.025%, otic solution alone. To evaluate the superiority

Patients' experience of necrotising otitis externa: a qualitative study. Necrotising otitis externa is a serious infective condition. Patients are typically frail, diagnostic delay is common and severe pain is a key feature. This study aimed to qualitatively analyse patient-centred data to identify key themes in the patient's experience. Open-ended questionnaires were sent to 28 patients . Responses were qualitatively analysed using a grounded theory approach. Iterative cycles were used to develop codes using a constant comparison technique. Emerging categories were refined to identify core themes. Four main themes emerged: severe pain, mental health, quality of life and diagnostic delays. This is the first study to explore patients' perspectives in necrotising otitis externa. It indicates

Efficacy and safety of a hydrocortisone aceponate-containing ear spray solution in dogs with erythemato-ceruminous otitis externa: A randomised, multicentric, single-blinded, controlled trial. Erythemato-ceruminous otitis externa (ECOE) is frequently seen in dogs affected with an allergic skin disease, with recurrent secondary bacteria and yeast overgrowths (detected on cytological examination ) or the commercially available ear treatment control product group (CTRL). Dogs were treated for 7-14 days, as needed. At Day (D)0, D7, D14, D28 and D42, Otitis Index Score-3, hearing test, pruritus and pain visual analogue scales, and cytological scores were graded. The overall response to treatment also was assessed. All clinical parameters decreased rapidly and in a similar way without any significant difference

Ciprofloxacin 3mg/mL + dexamethasone 1mg/mL ear drops (Cilodex) - Acute otitis media in patients with tympanostomy tubes (AOMT) and Acute otitis externa

Clinical commissioning policy: Hyperbaric oxygen therapy for malignant otitis externa NHS England » Clinical commissioning policy: Hyperbaric oxygen therapy for malignant otitis externa (all ages) Skip to main content Cookies on the NHS England websiteWe’ve put some small files called cookies on your device to make our site work.We’d also like to use analytics cookies. These send information * Commissioning * Get involvedOur advice for clinicians on the coronavirus is here.If you are a member of the public looking for information and advice about coronavirus (COVID-19), including information about the COVID-19 vaccine, go to the NHS website. You can also find guidance and support on the GOV.UK website.Clinical commissioning policy: Hyperbaric oxygen therapy for malignant otitis externa (all ages

Exploring theories for the exponential 16-year rise in incidence of necrotising otitis externa in England. Necrotising otitis externa is a severe, life-threatening infection. Epidemiological data demonstrate a dramatic rise in reported cases in England from 2002 to 2017. The reasons for this remain elusive. A quantitative descriptive study was undertaken using epidemiological data from the Hospital Episode Statistics database. Cases from 2002 to 2017 were compiled and analysed. Four potential theories were explored to explain the rise in incidence. Within the 16-year period, 7327 necrotising otitis externa cases were reported. Annual necrotising otitis externa incidence increased 1142 per cent within the 16-year period, from 123 recorded cases in 2002 to 1405 cases in 2017. This correlates

Use of a modified Burow's solution to treat canine otitis externa: A randomised comparative clinical study. Given the increase in antimicrobial drug resistance of several pathogens that affect the ear, there is a need for alternative therapy for canine otitis externa (OE). We hypothesised that the efficacy of modified Burow's solution would be non-inferior to that of standard treatment

Immunosuppression, infection, and epidermal compromise: an aetiological triad for necrotising otitis externa that highlights potential modifiable risk factors. A key clinical feature of necrotising otitis externa is granulation tissue arising from the ear canal, representing epidermal compromise. The aim of this work was to explore the role of epidermal compromise in the aetiology of necrotising otitis externa. A structured risk factor history was taken from 54 patients diagnosed with necrotising otitis externa between 2017 and 2022. Primary care records were also reviewed. A total of 94 per cent of patients reported incidents of potential epidermal compromise preceding severe pain onset, including a 35 per cent incidence of ear syringing. A total of 94 per cent of patients were